Speculative Drug Developers Take Aim at Blockbuster Status - SYS-CON Media (press release) PDF Print
SYS-CON Media (press release)
Keryx Biopharmaceuticals develops pharmaceuticals for the treatment of diseases such as diabetes, renal disease and cancer. The company's oral, iron-based drug "Zerenex" is in phase III testing under a Special Protocol Assessment agreement with the FDA

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.

Notice: Undefined variable: query in /home/globaldi/public_html/components/com_joomlawatch/class.joomlawatch.db.php on line 129